University of Strathclyde
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Mironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases
Mironid is a Glasgow-based biopharmaceutical company developing small molecule therapeutics for Autosomal Dominant Polycystic Kidney Disease, a life-threatening hereditary kidney disease with limited treatment options. Its first-in-class LoAc drug candidates target the abnormally high kidney cAMP levels that drive the uncontrolled growth of fluid-filled cysts.
Regeno secures £420k in funding from SFC and One Planet Capital for ground-level serviceable wind turbines
Regeno develops wind turbines that can be serviced from ground level to reduce installation and maintenance costs. Its design allows parts to be replaced without cranes or specialised offshore equipment, making wind energy more accessible for businesses and communities.
Sentinel secures £1.2m funding led by SFC Capital to expand its trauma support platform for frontline workers
Sentinel provides a digital platform for trauma prevention and support, designed with frontline workers to improve resilience, wellbeing and recovery in high-stress professions.
More venture news
- 3 Aug 2026
OlixOLIX unlocks £240m Series B led by Fundomo to develop specialised AI inference chips for each stage of token production
Series BDeep Tech - 5 Aug 2026
MironidMironid raises a £34m Series B including £8.4m from Scottish National Investment Bank to advance small molecule treatments for kidney diseases
Series BLife Sciences - 29 Jul 2026
GreyparrotGreyparrot raises £20m Series B from angels for AI camera systems that read waste on recycling belts
Series BClimate